MedPath

Differences In The Severity Of Diabetic Neuropathy Based On Electromyography In Type 2 Diabetes Mellitus Patients With And Without Comorbidities

Completed
Conditions
Diabetic Neuropathies
Interventions
Diagnostic Test: Electromyography
Registration Number
NCT06573684
Lead Sponsor
Universitas Diponegoro
Brief Summary

The goal of this clinical trial is to learn the differences severity level of diabetic neuropathy based on electromyelography in type II diabetic patient with and without comorbidities. The main questions of this study:

1. What is the electromyography result in type II diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia?

2. Is there any differences in electromyography result in type II diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia?

3. Is there any association between distal latency with nerve conduction velocity in type II diabetic patient with and without comorbidities?

4. Is there any association between distal latency with amplitude in type II diabetic patient with and without comorbidities?

5. Is there any differences on diabetic neuropathy severity based on age, height, and A1C levels in type II diabetic patient with and without comorbidities?

Researchers will collect information based on hospital registry as secondary data of in type II diabetic patient with and without comorbidities. The data consist of demographic data, clinical presentation, laboratory, and electromyography were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
78
Inclusion Criteria
  • Diabetic neuropathy patient who classified as distal symmetrical polyneuropathy
  • Diabetic neuropathy patient who has no comorbidities
  • Diabetic neuropathy patient who has hypertension
  • Diabetic neuropathy patient who has hypertension and dyslipidemia
Exclusion Criteria
  • Diabetic neuropathy patient with history of chemotherapy
  • Diabetic neuropathy patient with history of hernia nucleus pulposus
  • Diabetic neuropathy patient with history of CKD stage V or on routine dyalisis
  • Missing data on medical record

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Type II Diabetic Mellitus with hypertensionElectromyographyPatient who suffered diabetic neuropathy and history of type II diabetic mellitus with hypertension
Type II Diabetic Mellitus with hypertension and dyslipidemiaElectromyographyPatient who suffered diabetic neuropathy and history of type II diabetic mellitus with hypertension and dyslipidemia
Type II Diabetic Mellitus without comorbiditiesElectromyographyPatient who suffered diabetic neuropathy and history of type II diabetic mellitus without comorbidities
Primary Outcome Measures
NameTimeMethod
Distal LatencyElectromyography examination was done approximately 1 year after clinical onset of neuropathy appear

Distal latency defined as time between stimuli until deflection of Compound Muscle Action Potentials (CMAP) from baseline

Secondary Outcome Measures
NameTimeMethod
AmplitudeElectromyography examination was done approximately 1 year after clinical onset of neuropathy appear

Amplitude define as the height of first negative deflection of Compound Muscle Action Potentials (CMAP) from baseline

Nerve Conduction VelocityElectromyography examination was done approximately 1 year after clinical onset of neuropathy appear

Nerve Conduction Velocity defined as the measurement of axon conduction velocity by dividing space of nerve conduction with time needed

Trial Locations

Locations (1)

Dr. Kariadi Central General Hospital

🇮🇩

Semarang, Central Of Java, Indonesia

© Copyright 2025. All Rights Reserved by MedPath